Effects of 18-month Vildagliptin Treatment on Portal Vein Pressure and Hepatosteatosis

KARATOPRAK C., Kilicarslan R., ÇAKIRCA M., Aydin S., Ozkan T., ZORLU M., ...Daha Fazla

BEZMIALEM SCIENCE, cilt.7, sa.4, ss.317-321, 2019 (ESCI, TRDizin) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 7 Sayı: 4
  • Basım Tarihi: 2019
  • Doi Numarası: 10.14235/bas.galenos.2019.2892
  • Dergi Adı: BEZMIALEM SCIENCE
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.317-321
  • İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

Objective: Patients with type 2 diabetes have an increased tendency to develop hepatosteatosis. The effects of drugs used to treat diabetes on the liver, regardless of the disease, are unknown.The aim of this study was to investigate the effects of vildagliptin, a dipeptidyl peptidase-4 inhibitor, on the portal vein pressure and hepatosteatosis in patients with type 2 diabetes in the 18 months of follow-up.